Merit Medical Systems announced positive 6-month patency results from the WRAP Global Registry for their WRAPSODY Cell-Impermeable Endoprosthesis (CIE), used to maintain vascular access in hemodialysis patients. The study showed a 92.7% target lesion primary patency and 76.7% access circuit primary patency, outperforming previous clinical trial results. These real-world findings support the device's effectiveness in routine practice and may boost physician confidence in treating vascular access issues. The WRAPSODY device is approved in the US, Canada, Europe, and Brazil, with ongoing studies to further validate its clinical benefits.
Merit Medical's real-world data on vascular access devices is presented here alongside Pluang's health sector snapshot as of Nov 05, 2026 20:51 WIB: Among 150 US health stocks, 88 advanced and 58 declined. Twist Bioscience Corp (TWST) traded at USD 136.00 with a 4.61% drop and 99% sell orders, contrasting with Nuwellis Inc (NUWE) at USD 5.50 gaining 4.36% despite 92% sell orders, while Iovance Biotherapeutics Inc (IOVA) held steady near USD 8.33 with a near-even buy-sell split and a notably short typical hold time of 4 days.
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
